MORRIS JESSICA EDGAR 4

What Happened

• Jessica Edgar Morris, Chief Operating Officer of Tonix Pharmaceuticals (TNXP), was granted two derivative awards on Feb 24, 2026 totaling 78,023 shares (39,012 and 39,011). Each award is reported at $0.00 per share (total reported acquisition value $0) and is recorded as a derivative/security award.

Key Details

• Transaction date: 2026-02-24; Form 4 filed: 2026-02-26 (within the typical 2-business-day reporting window).
• Awards: 39,012 and 39,011 derivative shares; combined total = 78,023.
• Reported price: $0.00 per share; reported acquisition value: $0 (award/grant, not an open-market purchase).
• Vesting/plan notes from the filing:
  • F1: "One-third of the option vests on the first anniversary of issuance and 1/48th each month thereafter for 36 months."
  • F2: "The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended."
• Shares owned after the transaction: Not disclosed in this Form 4.

Context

• These entries are derivative awards (stock option grants) that vest over time per the footnote schedule — they are compensation/retention grants, not immediate purchases or sales. Because they are awards rather than open-market buys, they do not represent a direct cash outlay by the insider at grant and do not indicate immediate selling activity.